MOONLAKE IMMUNOTHERAPEUTICS's ticker is and the CUSIP is 61559X104. A total of 122 filers reported holding MOONLAKE IMMUNOTHERAPEUTICS in Q3 2023. The put-call ratio across all filers is 13.14 and the average weighting 1.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $11,422,230 | +124.8% | 200,390 | +101.1% | 0.01% | +133.3% |
Q2 2023 | $5,081,640 | +252.9% | 99,640 | +48.0% | 0.01% | +200.0% |
Q1 2023 | $1,439,804 | +103.7% | 67,312 | 0.0% | 0.00% | +100.0% |
Q4 2022 | $706,776 | +31.4% | 67,312 | 0.0% | 0.00% | 0.0% |
Q3 2022 | $538,000 | +253.9% | 67,312 | +132.4% | 0.00% | – |
Q2 2022 | $152,000 | – | 28,966 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BVF INC/IL | 21,751,284 | $1,239,823,188 | 33.43% |
Cormorant Asset Management, LP | 8,142,100 | $464,099,700 | 27.07% |
Ally Bridge Group (NY) LLC | 183,105 | $10,436,985 | 12.25% |
Finepoint Capital LP | 331,416 | $18,890,712 | 9.41% |
Ghost Tree Capital, LLC | 330,000 | $18,810,000 | 6.19% |
5AM Venture Management, LLC | 313,210 | $17,852,970 | 5.14% |
Ghost Tree Capital, LLC | 250,000 | $14,250,000 | 4.69% |
MPM BioImpact LLC | 294,190 | $16,768,830 | 4.48% |
Integral Health Asset Management, LLC | 500,000 | $28,500,000 | 3.95% |
Altium Capital Management LP | 88,000 | $5,016,000 | 2.62% |